Research Topics
Species | Jay N CohnSummaryAffiliation: University of Minnesota Country: USA Publications
| Collaborators
|
Detail Information
Publications
Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)Jay N Cohn
Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Eur J Heart Fail 5:659-67. 2003....- Screening for early detection of cardiovascular disease in asymptomatic individualsJay N Cohn
Rasmussen Center for Cardiovascular Disease Prevention, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minn, USA
Am Heart J 146:679-85. 2003..The objective of the current study is to screen individuals with vascular and cardiac tests aimed at identifying early abnormalities likely to progress and to measure risk contributors susceptible to therapy... - Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Pro positionJay N Cohn
Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Curr Hypertens Rep 4:307-10. 2002..These data emphasize the need for trials in black patients to identify effective therapy. The first such trial, African-American Heart Failure Trial, is currently underway... - Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure TrialJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, Minn 55455, USA
Circulation 108:1306-9. 2003..The Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone levels in patients with NYHA class II through IV heart failure... - Efficacy and safety in clinical trials in cardiovascular diseaseJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
J Am Coll Cardiol 48:430-3. 2006..This revised approach, made possible by our enhanced ability to monitor the progression of disease, should make it possible to study earlier disease and to improve cardiovascular health while reducing health care costs... 
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemiaJay N Cohn
Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA
Am J Hypertens 22:137-44. 2009..This nested substudy of the AVALON trial assessed the effects of coadministered amlodipine and atorvastatin vs. either therapy alone or placebo on arterial compliance, to evaluate the vascular benefits of coadministered therapy...- Comprehensive noninvasive arterial vascular evaluationJay N Cohn
Cardiovascular Division, Mayo Mail Code 508, Minneapolis, MN 55455, USA
Future Cardiol 5:573-9. 2009..This can provide insight into functional and structural abnormalities in the small as well as the large arteries, and may be useful in monitoring response to therapy... - Surrogate markers for cardiovascular disease: functional markersJay N Cohn
Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, Minn 55455, USA
Circulation 109:IV31-46. 2004 - Time to foster a rational approach to preventing cardiovascular morbid eventsJay N Cohn
Rasmussen Center for Cardiovascular Disease Prevention, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
J Am Coll Cardiol 52:327-9. 2008..More extensive data to confirm the sensitivity and specificity of this scoring system and to demonstrate its utility in tracking the response to therapy are needed to justify widespread application in clinical practice... - Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?Jay N Cohn
University of Minnesota Medical School, Minneapolis, MN 55455, USA
Nat Clin Pract Cardiovasc Med 5:526-7. 2008..Physicians should also recognize that the design of the study, in which full doses of the ACE inhibitor and the ARB were administered, might not replicate clinical practice, where one drug is usually added to the other... - Direct-acting vasodilatorsJay N Cohn
Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN, USA
J Clin Hypertens (Greenwich) 13:690-2. 2011..Although nitrates have not achieved widespread use as antihypertensive agents, they are effective in producing sustained blood pressure (BP) reductions when added to other antihypertensive regimens... - Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatmentJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455, USA
Hypertension 46:217-20. 2005.... - Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFTJay N Cohn
Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN 55455, USA
Congest Heart Fail 12:127-31. 2006..The combination of ACEIs and BBs exerts a greater mortality reduction than suggested from clinical trials and reduces pump failure mortality to 1% per year... - Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiologyJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota 55455, USA
Am J Cardiol 97:4F-12F. 2006..A review of animal and human studies with aldosterone blockers reveals improvement in, and in some cases complete reversal of, these pathophysiologic effects of aldosterone on the cardiovascular system... - Monitoring vascular health beyond blood pressureDaniel A Duprez
Rasmussen Center for Cardiovascular Disease Prevention, Medical School, University of Minnesota, 420 Delaware Street SE, Minneapolis, 55455, USA
Curr Hypertens Rep 8:287-91. 2006.... 
A-HeFT: old dog, new endothelial tricksJay N Cohn
Rasmussen Center for Cardiovascular Disease Prevention, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
Tex Heart Inst J 32:366-8. 2005..The potential benefit of this therapy in other groups with heart failure and in other vascular remodeling disease processes requires further study...- Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?Jay Cohn
Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota 55455, USA
J Card Fail 15:199-205. 2009..Other end points are now being considered and implemented because of the recognized limitations associated with using mortality and morbidity as the sole measures of therapeutic efficacy... - New approaches to screening for vascular and cardiac riskJ N Cohn
Department of Medicine, University of Minnesota, Minneapolis 55455, USA
Am J Hypertens 14:218S-220S. 2001..The usefulness of these early screening techniques to encourage tailored interventions in susceptible individuals needs to be explored in large-scale trials... - Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failureJay N Cohn
Cardiovascular Division, University of Minnesota Medical School, Minneapolis, Minnesoata 55455, USA
J Renin Angiotensin Aldosterone Syst 4:137-9. 2003.... - The James B. Herrick Award Lecture. 2003. Clinical research: whose agenda is it?Jay N Cohn
Cardiovascular Division, Department of Medicine, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, Minn 55455, USA
Circulation 109:2256-62. 2004 - Should the blood pressure or the blood vessel be the target of therapy?Jay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Expert Rev Cardiovasc Ther 9:1397-401. 2011.... - Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure TrialAnne L Taylor
Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
Circulation 115:1747-53. 2007.... - C-reactive protein in heart failure: prognostic value and the effect of valsartanInder S Anand
VA Medical Center, Minneapolis, MN 55417, USA
Circulation 112:1428-34. 2005..We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan... - Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure TrialInder S Anand
VA Medical Center, Minneapolis, Minnesota, USA
J Am Coll Cardiol 49:32-9. 2007.... - Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trialAnne L Taylor
Department of Medicine, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York 10032, USA
J Card Fail 18:600-6. 2012..In this analysis, we investigated treatment effects by age <65 or ≥65 years... - Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot StudyDaniel A Duprez
Rasmussen Center for Cardiovascular Disease Prevention, Cardiovascular Division, VCRC Room 270, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street Southeast, Minneapolis, Minnesota 55455, USA
J Am Coll Cardiol 50:835-9. 2007.... - Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Inder S Anand
VA Medical Center and University of Minnesota, Minneapolis, Minn 55417, USA
Circulation 107:1278-83. 2003..We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over time are associated with corresponding changes in mortality and morbidity in the Valsartan Heart Failure Trial... - Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failureInder S Anand
VA Medical Center, Cardiology 111 C, Minneapolis, Minn 55417, USA
Circulation 120:1577-84. 2009..Renin-angiotensin blockade medications improve outcomes in HF but are underutilized in HF patients with renal dysfunction because of safety concerns and a lack of evidence of their effectiveness... - Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFTJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
J Card Fail 13:331-9. 2007..Whether the fixed-dose combination produces a further regression of LV remodeling when added to renin-angiotensin and sympathetic inhibitors has not been documented... - Outcomes by gender in the African-American Heart Failure TrialAnne L Taylor
Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
J Am Coll Cardiol 48:2263-7. 2006..We therefore compared outcomes by gender and treatment... - Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure TrialInder S Anand
Cardiology 111 C, VA Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA
Circulation 122:1387-95. 2010..Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure... - Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observationsDaniel A Duprez
Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
J Am Soc Hypertens 5:401-9. 2011..Identifying early disease in asymptomatic individuals provides a better guide to the need for preventive therapy than traditional risk factor assessment... - What is the role of angiotensin-receptor blockade in cardiovascular protection?Jay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
Am Heart J 152:859.e1-8. 2006..A preliminary trial is under way to evaluate the role of angiotensin receptor blockade as preventive treatment of individuals with early signs of vascular or cardiac disease... - Combination of isosorbide dinitrate and hydralazine in blacks with heart failureAnne L Taylor
Department of Medicine Cardiology, University of Minnesota Medical School, Minneapolis 55455, USA
N Engl J Med 351:2049-57. 2004..We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy... - Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFTInder S Anand
VA Medical Center, Minneapolis, MN 55417, USA
Circulation 112:1121-7. 2005..Anemia is known to be a prognostic marker for patients with heart failure. However, little is known about the prognostic value of changes in hemoglobin (Hgb) over time or about the causes of anemia... - Measuring endothelial functionChristopher J Lockhart
Cardiovascular Division, Mayo Mail Code 508, University of Minnesota, Minneapolis, MN, 55455, USA
Curr Diab Rep 6:267-73. 2006..In this article, we critically appraise the use of different methodologies employed to study endothelial function as a surrogate marker of future cardiovascular risk... - Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapyJay N Cohn
Rasmussen Center for Cardiovascular Disease Prevention, Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
Am J Hypertens 21:248-56. 2008..Trials designed to document such efficacy are currently underway... - Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of lifeThomas S Rector
Center for Chronic Disease Outcomes Research, Department of Veterans Affairs Medical Center, 152/2E, One Veterans Drive, Minneapolis, MN 55417, USA
J Card Fail 12:87-92. 2006..Further studies are needed to understand the relationships between heart failure pathology and symptoms and to identify determinants of the effects of heart failure on patients' quality of life that were not related to symptoms... - Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure TrialInder S Anand
VA Medical Center, Cardiology, Minneapolis, MN 55417, USA
Circ Heart Fail 1:34-42. 2008..The aim of the present study was to investigate the relationship between the SBP-lowering effects of valsartan and its cardiovascular protective effects in this population... - The African-American Heart Failure Trial: background, rationale and significanceAnne L Taylor
University of Minnesota, Minneapolis, USA
J Natl Med Assoc 94:762-9. 2002..Besides additional testing of H+ISDN in HF, A-HeFT will be the first HF trial aimed at a subgroup of African American patients, as well as the first to use a new composite HF score as its primary efficacy endpoint... - Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular eventsElizabeth Grey
Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis 55455, USA
Am J Hypertens 16:265-9. 2003..50, P <.001), whereas C(1) was no longer predictive. CONCLUSION: Reduced small artery elasticity, which is a measure of endothelial dysfunction, is significantly associated with cardiovascular events independent of age... - Nitric oxide's role in heart failure: pathophysiology and treatment. IntroductionJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA
J Card Fail 9:S197-8. 2003 - Determinants of radial artery pulse wave analysis in asymptomatic individualsDaniel A Duprez
Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota 55455, USA
Am J Hypertens 17:647-53. 2004.... - Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone systemJay N Cohn
Rasmussen Center for Cardiovascular Disease Prevention, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
Adv Ther 24:1290-304. 2007..Results from ongoing, large-scale, clinical endpoint trials will provide important additional information about the benefits of dual RAAS inhibition in patients at high risk for CV morbidity and mortality... - Identifying early cardiovascular disease to target candidates for treatmentDaniel A Duprez
Cardiovascular Division, Rasmussen Center for Cardiovascular Disease Prevention, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
J Clin Hypertens (Greenwich) 10:226-31. 2008..Each test is individually scored, and the total disease score is the sum of all the test scores. A study is ongoing to compare the new disease score vs the classical Framingham risk estimate in the prediction of cardiovascular events... - A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureJ N Cohn
Department of Medicine, University of Minnesota Medical School, Minneapolis, 55455, USA
N Engl J Med 345:1667-75. 2001..However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination... - Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failureJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
Am J Cardiol 90:992-3. 2002 - Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathyBarry J Maron
Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, and University of Minnesota, Minneapolis, MN 55407, USA
Circulation 109:984-9. 2004..Plasma B-type natriuretic peptide (BNP) has been used widely as an objective marker for heart failure severity and outcome, predominantly in coronary heart disease with ventricular dilatation and systolic dysfunction... - Clinical experience with perindopril in African-American hypertensive patients: a large United States community trialJay N Cohn
Cardiovascular Division, University of Minnesota Medical School, Box 508, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Am J Hypertens 17:134-8. 2004..The prevalence of hypertension is greater in African Americans, and management of this condition presents challenges for practicing physicians... - Introduction to surrogate markersJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
Circulation 109:IV20-1. 2004 - Arterial stiffness as a risk factor for coronary atherosclerosisDaniel A Duprez
Cardiovascular Division, VCRC Room 270, University of Minnesota, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA
Curr Atheroscler Rep 9:139-44. 2007..Promising study results show that measurement of arterial stiffness could become an important part of the routine assessment of patients in daily practice... - Left ventricle and arteries: structure, function, hormones, and diseaseJ N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, USA
Hypertension 37:346-9. 2001..Thus, progression of cardiovascular disease is largely a consequence of structural changes that are hormonally mediated and may be inhibited by drug therapy... - Blood pressure and arterial compliance in young adults: the Minnesota Children's Blood Pressure StudyD K Arnett
Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55454 1015, USA
Am J Hypertens 14:200-5. 2001..008 mL/mm Hg change in C2. Data from the Minnesota Children's Blood Pressure Study indicate that systolic BP is inversely related to arterial compliance, particularly C1 (the large artery, or capacitive compliance)... - Relationship between C-reactive protein and arterial stiffness in an asymptomatic populationD A Duprez
Department of Medicine, Rasmussen Center for Cardiovascular Disease Prevention, Cardiovascular Division, University of Minnesota Medical School, Minneapolis, 55455, USA
J Hum Hypertens 19:515-9. 2005.... - Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT InvestigatorsJ N Cohn
University of Minnesota Medical School, Box 508, 420 Delaware Street S E, Minneapolis, MN 55455, USA
Eur J Heart Fail 2:439-46. 2000..A total of 5010 patients with an ejection fraction <40% have been randomized to either valsartan titrated to 160 mg b.i.d. or to placebo... - Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFTInder S Anand
VA Medical Center, Minneapolis, MN, USA
Eur J Heart Fail 15:511-8. 2013..This study was conducted to determine whether galectin-3, a β-galactoside-binding lectin, plays a role in the pathogenesis of heart failure (HF)... - Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarctionMichael D Miedema
University of Minnesota Cardiovascular Division, Minneapolis, MN 55407, USA
Am Heart J 164:259-67. 2012..Even in the presence of multiple cardiovascular risk factors, many patients are not considered high risk and are not offered preventive medications despite proven efficacy... - Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trialInder Anand
Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN, USA
Lancet 364:347-54. 2004..Thus, endothelin(A) blockade is unlikely to be useful as an add-on treatment in such patients... - Arterial compliance abnormalities in isolated systolic hypertensionA Beltran
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis 55455, USA
Am J Hypertens 14:1007-11. 2001..This abnormality cannot be accurately assessed by pulse pressure alone... - Endothelial dysfunction and the metabolic syndromeGary E McVeigh
Cardiovascular Division, Mayo Mail Code 508, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Curr Diab Rep 3:87-92. 2003..Noninvasive assessment of vascular health may also aid the clinical decision-making process by guiding therapeutic interventions to optimize vascular protection in the metabolic syndrome... - Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertensionMasood Gilani
Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA Current address Bay Pines VA Hospital, St Petersburg, Florida, USA
J Am Soc Hypertens 1:45-55. 2007..Reduction in small artery compliance was a sensitive marker for this induced endothelial dysfunction and may serve as a useful marker for pre-hypertensive patients at risk for cardiovascular morbid events... - New therapeutic strategies for heart failure: left ventricular remodeling as a targetJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
J Card Fail 10:S200-1. 2004..The growing evidence that structural remodeling represents the disease of heart failure has now fueled mechanical as well as pharmacologic approaches to inhibiting the remodeling... - Reduced vascular compliance as a marker for essential hypertensionG E McVeigh
Department of Medicine, University of Minnesota Medical School, Minneapolis
Am J Hypertens 4:245-51. 1991.... - Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision makingJ N Cohn
Cardiovascular Division, University of Minnesota Medical School, Minneapolis 55455, USA
Am J Hypertens 14:258S-263S. 2001..Further research is needed to confirm whether this method offers a means of improving risk stratification and therapeutic decision making... - Global structural ventricular remodeling: summationJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
J Card Fail 8:S269-70. 2002 - Beta-blockers for heart failureJay N Cohn
Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
J Card Fail 9:458. 2003 - Non-invasive studies of peripheral vascular compliance using a non-occluding photoplethysmographic methodE A López-Beltrán
Biomedical Engineering Program, University of Minnesota, USA
Med Biol Eng Comput 36:748-53. 1998..The results suggest that Cindex may be a useful noninvasive indicator of peripheral vascular compliance in humans... - Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in manJ N Cohn
Hypertension and Clinical Hemodynamics Section, Veterans Administration Hospital, Department of Medicine, Georgetown University School of Medicine, Washington, DC, USA
Circulation 38:151-7. 1968..It is concluded that PLV-2 in small doses produces renal vasodilation and in larger doses preferential extra-renal vasoconstriction resulting in redistribution of blood flow to the kidney... - Heart failure: future treatment approachesJ N Cohn
University of Minnesota Medical School, Minneapolis 55455, USA
Am J Hypertens 13:74S-78S. 2000..The long-term solution to this clinical problem is to develop sensitive and reliable markers that can predict response in individual patients or monitor effectiveness of therapy... - Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational studyStefan D Anker
Applied Cachexia Research, Department of Cardiology, Charite, Campus Virchow Klinikum, Berlin, Germany
Lancet 361:1077-83. 2003..We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors... - Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Aldo P Maggioni
ANMCO Research Center, Florence, Italy
Am Heart J 149:548-57. 2005..The aims of these subanalyses of Val-HeFT were to assess (a) the effects of valsartan in the prevention of AF, (b) the independent predictors of this event, and (c) the prognostic role of AF occurrence... - Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failureKarl Swedberg
Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
Circulation 105:1797-803. 2002..We investigated the dose-response relationship of a new sustained-release (SR) preparation of moxonidine and the plasma concentration of norepinephrine in patients with chronic heart failure... - Effect of Valsartan on hospitalization: results from Val-HeFTPeter Carson
Department of Veterans' Affairs, Medical Center, Washington, DC 20422, USA
J Card Fail 9:164-71. 2003..6%) than single hospitalizations (-8.7%). CONCLUSIONS: Addition of valsartan to prescribed HF therapy demonstrated significant reductions in HF hospitalizations and was particularly beneficial in reducing recurrent HF hospitalization... - Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)Roberto Latini
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Circulation 106:2454-8. 2002..The long-term effects of angiotensin receptor blockers on BNP and NE in heart failure patients are not known... - Sympathetic nervous system in heart failureJay N Cohn
Circulation 106:2417-8. 2002 - Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitorsAldo P Maggioni
ANMCO Research Center, Florence, Italy
J Am Coll Cardiol 40:1414-21. 2002.... - Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic studyMaylene Wong
VA Greater Los Angeles Healthcare System and University of California at, Los Angeles, California 90073, USA
J Am Coll Cardiol 40:970-5. 2002..The objective of the study was to evaluate the effect of an angiotensin receptor blocker on left ventricular (LV) structure and function when added to prescribed heart failure therapy... - African-American Heart Failure Trial (A-HeFT): rationale, design, and methodologyJoseph A Franciosa
Zena and Michael A. Wiener Cardiovascular Institute, Mt. Sinai School of Medicine, New York, New York, USA
J Card Fail 8:128-35. 2002..CONCLUSIONS: In addition to providing additional information on BiDil efficacy in HF, A-HeFT is the first HF trial aimed at a selected subgroup of patients and the first to use a new composite HF score as its primary efficacy endpoint... - Techniques for studying arterial elastic propertiesJay N Cohn
Hypertension 39:e20. 2002 - Ventricular remodeling in heart failure: a credible surrogate endpointMarvin A Konstam
J Card Fail 9:350-3. 2003 - Antihypertensive utility of perindopril in a large, general practice-based clinical trialStevo Julius
Division of Hypertension, University of Michigan, Ann Arbor, MI 48109, USA
J Clin Hypertens (Greenwich) 6:10-7. 2004..Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal... - The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)Serge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
J Card Fail 12:375-80. 2006..In this setting, BNP remained the strongest neurohormonal prognostic factor... - Incremental prognostic value of changes in B-type natriuretic peptide in heart failureRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Am J Med 119:70.e23-30. 2006..We hypothesized that B-type natriuretic peptide changes during treatment of heart failure may provide independent information on disease progression and outcome in patients enrolled in the Val-HeFT trial... - Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT TrialDennis M McNamara
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
J Am Coll Cardiol 48:1277-82. 2006..We sought to evaluate the effect of the aldosterone synthase promoter polymorphism on heart failure outcomes for subjects in the African American Heart Failure Trial (A-HeFT)... - Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFTMaylene Wong
VA Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA, Los Angeles, USA
Eur J Heart Fail 8:502-8. 2006..Clinical trials emphasize mortality and morbidity endpoints... - The use of race and ethnicity in medicine: lessons from the African-American Heart Failure TrialJay N Cohn
Rasmussen Center for Cardiovascular Disease Prevention at the University of Minnesota, USA
J Law Med Ethics 34:552-4, 480. 2006..Application of these findings need not be confined to the population studied, but the observation highlights the need for more precise ways to identify individual responsiveness to therapy... - Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure TrialGiuseppina Majani
Salvatore Maugeri Foundation, Psychology Unit, Institute of Care and Scientific Research, Montescano, Pavia, Italy
J Card Fail 11:253-9. 2005..0% versus 30.2%). CONCLUSION: Valsartan compared to placebo added to prescribed therapy slows progressive worsening of QOL in patients with heart failure... - Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT)Lawrence Baruch
Bronx VA Medical Center, Bronx, NY 10468, USA
Am Heart J 148:951-7. 2004..As the prevalence of HF morbidity and mortality are increased in the elderly, the effect of valsartan in the elderly is of clinical significance... - Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFTHenry Krum
Monash University Medical School, Alfred Hospital, Melbourne, Australia
Eur J Heart Fail 6:937-45. 2004..To investigate the effect of valsartan in the Valsartan-Heart Failure Trial (Val-HeFT) when added to angiotensin-converting enzyme inhibitor (ACEi) alone in patients with heart failure (HF)... - Myocardial structural effects of aldosterone receptor antagonism in heart failureJay N Cohn
J Am Coll Cardiol 50:597-9. 2007 - Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic dataMaylene Wong
Veterans Affairs Greater Los Angeles Healthcare System, and David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California 90073, USA
J Am Coll Cardiol 43:2022-7. 2004..The objective of this study was to test the hypothesis that the severity of left ventricular remodeling predicts the response to treatment and outcomes in chronic heart failure... - Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradoxS William Tam
NitroMed, Inc, Lexington, Massachusetts 02421, USA
Clin Pharmacokinet 46:885-95. 2007.... - The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFTRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Eur Heart J 25:292-9. 2004..Mainly because of small sample size, the predictive value of different NH has never been compared, while taking into account demographic, clinical and echocardiographic markers of risk in HF... - Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure TrialJalal K Ghali
University Health Center, Wayne State University, Detroit, MI 48201, USA
Am J Cardiovasc Drugs 7:373-80. 2007.... - Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trialLidia Staszewsky
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
J Card Fail 13:797-804. 2007..Because little information is available about the population of patients with both syndromes, we assessed the characteristics and the independent contribution of COPD to outcomes in patients with stable chronic heart failure... - Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) dataSerge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Clin Chem 52:1528-38. 2006..This work aimed to provide a direct comparison of the prognostic value of BNP and NT-proBNP in patients with chronic and stable HF...